Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Do ARBs increase MI risk?

In 2004, an editorial in the British Medical Journal raised a concern that Angiotensin II Receptor Blockers (ARBs) may increase the risk of myocardial infarction.

Since this article several reviews have been published that have dismissed the link however two new articles [subscription required] published in Circulation may revive the debate.

In both articles the authors have conducted reviews of available evidence using different inclusion criteria. One article concludes that MI event risk is increased in ARB users, the other finds no difference between ARB users and control subjects.

The common ground shared by the two papers is that Angiotensin Converting Enzyme Inhibitors (ACEIs) are superior to ARBs. Furthermore, neither paper demonstrated that ARBs actually reduce MI risk; ARBs may not be "ACEIs without a cough".

Action: ACEIs remain the first line drug choice in this class of medicines. ARBs should only be used when ACEIs are not tolerated and in these cases patients should be informed of the differences in MI risk.

Share 'Do ARBs increase MI risk?' on Email Share 'Do ARBs increase MI risk?' on Delicious Share 'Do ARBs increase MI risk?' on Digg Share 'Do ARBs increase MI risk?' on Facebook Share 'Do ARBs increase MI risk?' on Google+ Share 'Do ARBs increase MI risk?' on reddit Share 'Do ARBs increase MI risk?' on StumbleUpon Share 'Do ARBs increase MI risk?' on Twitter

atomic-wealth

No Comments to “Do ARBs increase MI risk?”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,521 spam comments.

atomic-wealth
fond-illness
summer